Additionally of being the most frequent mutation in many types of cancers including PTC7, 11, BRAFV600E confers poorer prognosis compared to other oncogenes. There is a growing number of evidence demonstrating that BRAFV600E correlates with metastasis, cancer recurrence12 and higher mortality in PTC13. BRAFV600E-expressing cells have a diversity of malignant characteristics, including increased DNA synthesis, dedifferentiation, and chromosomal instability14. Also, BRAFV600E stimulates more actively MEK-dependent invasion than the expression of RET/PTC oncoprotein through the expression of matrix metalloproteinases (e.g. MMP-3, MMP-9 and MMP-13), which, in part, can explain the more aggressive BRAFV600E-induced phenotype15.